Impact of hematological markers in prediction of severity of cutaneous drug eruptions
Keywords:
NLR, PLR, Drug eruptionAbstract
Background Recognition of parameters to predict severity of drug eruptions can be helpful in early intervention in severe cases. In this study, we evaluate the role of hematological factors including neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte (PLR) ratio in prediction of severity in cutaneous drug reactions. Methods This is a retrospective cross-sectional study on 46 hospitalized patients with drug eruptions and 46 healthy individuals as control group. NLR/PLR was compared between patients with drug eruptions and healthy control group by independent t test. Moreover, the values of these hematological markers were compared between serious and non-serious types of drug eruptions by independent t test. Results Serious drug eruptions constitute nearly one-fourth of total drug eruptions. The mean values of NLR in case and control groups were 3.91±2.87 and 2.30±1.62, respectively (P=0.001). The mean values of PLR in case and control groups were 155.35±90.60 and 125±45.64, respectively (P=0.045). Females with drug eruptions had significantly higher PLR compared to males (P=0.02). Furthermore, there was no significant correlation between NLR/PLR in serious and non-serious types of drug reactions. Conclusion NLR/PLR was significantly higher in patients with drug eruptions compared to control group. There was no significant correlation between NLR/PLR with either demographic features of patients or severity of drug eruption; except significantly higher PLR in female with drug eruptions compared to males.References
Owen CE, Jones JM. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis). Med Clin North Am. 2021;105(4):577-97.
Koh Y, Yap CW, Li SC. Development of a combined system for identification and classification of adverse drug reactions: Alerts Based on ADR Causality and Severity (ABACUS). J Am Med Inform Assoc. 2010;17(6):720-2.
Padmavathi S, Manimekalai K, Ambujam S. Causality, severity and preventability assessment of adverse cutaneous drug reaction: a prospective observational study in a tertiary care hospital. J Clin Diagn Res: JCDR. 2013;7(12):2765.
Sundaran S, Udayan A, Hareendranath K, . Study on the classification, causality, preventability and severity of adverse drug reaction using spontaneous reporting system in hospitalized patients. Pharmacy. 2018;6(4):108.
Sasidharanpillai S, Chathoth A, Khader A. Predictors of disease severity in drug reaction with eosinophilia and systemic symptoms. Indian J Dermatol Venereol Leprol. 2019;85(3):266-75.
Chang HH, Chiang SY, Chen PC. A system for reporting and evaluating adverse drug reactions of herbal medicine in Taiwan from 1998 to 2016. Sci Rep. 2021;11(1):1-1.
Yan Z, Feng Z, Jiao Z, et al. The severity of adverse drug reactions and their influencing factors based on the ADR monitoring center of Henan Province. Sci Rep. 2021;11(1):1-9.
Ithnin M, Rani MD, Abd Latif Z. Mobile app design, development, and publication for adverse drug reaction assessments of causality, severity, and preventability. JMIR Mhealth Uhealth. 2017;5(5):e6261.
Torres‐Navarro I, Briz‐Redón Á, Botella‐Estrada R. Accuracy of SCORTEN to predict the prognosis of Stevens‐Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta‐analysis. J Eur Acad Dermatol Venereol. 2020;34(9):2066-77.
Guégan S, Bastuji-Garin S, Poszepczynska-Guigné E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol. 2006;126(2):272-6.
Noe MH, Rosenbach M, Hubbard RA, et al. Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens-Johnson syndrome/toxic epidermal necrolysis-ABCD-10. JAMA Dermatol. 2019;155(4):448-54.
Su SC, Mockenhaupt M, Wolkenstein P,. Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis. J Invest Dermatol. 2017;137(5):1065-73.
Quinn AM, Brown K, Bonish BK, et al. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol. 2005;141(6):683-7.
Mizukawa Y, Hirahara K, Kano Y, et al. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms severity score: A useful tool for assessing disease severity and predicting fatal cytomegalovirus disease. J Am Acad Dermatol. 2019;80(3):670-8.
Yang AP, Liu JP, Tao WQ, et al. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020;84:106504.
Shah N, Parikh V, Patel N, et al. Neutrophil lymphocyte ratio significantly improves the Framingham risk score in prediction of coronary heart disease mortality: insights from the National Health and Nutrition Examination Survey-III. Int J Cardiol. 2014;171(3):390-7.
Ahbap E, Sakaci T, Kara E, et al. Neutrophil-to-lymphocyte ratio and platelet-tolymphocyte ratio in evaluation of inflammation in end-stage renal disease. Clin Nephrol. 2016;85(4):199-208.
Dundar ZD, Daye M. Neutrophil-to-lymphocyte ratio is a prognostic predictor in emergency department patients with cutaneous adverse drug reaction. Am J Emerg Med. 2021;47:279-83.
Wang Q, Lan YP, Qi B, et al. Neutrophil: lymphocyte ratio is associated with disease severity and mortality in patients with Stevens–Johnson syndrome/toxic epidermal necrolysis. J Dermatol. 2021;48(9):1394-400.
Komatsu-Fujii T, Chinuki Y, Niihara H, et al. The thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammation. Allergol Int. 2018;67(1):90-5.
